Malignant tumors of the nasa l cavity are rare. We report the case ofan elderly woman who consulted us with a 4ye ar history ofprogressive nasa l obstruction, occasional ep istaxis.fac ialpain, and watering ofthe ey es. A diagnosis ofolfactory neuroblastoma was established by histopathology and confirmed by immunohistoc hemistry: On stag ing, the mass was classified as a Kadish stage B tWIlO/: The mass was exc ised via a lateral rhinototny approach, and the tumor was p eeledaway comp letelyfrom the cribriform plate with endosc opes. The patient underwent po stoperative radiation, andshe wasfree ofrecurrenc e at fo llow -up 15 months later:
Introduction
Malign ant tumors of the nasal cavity are rare . Olfactory neuroblastomas (esthesioneuroblastomas) account for only 6% of the se neopl asms. ' Fewer than 1,000 case s have been report ed in the literature since this tumor was first described more than 75 years ago.' These lesions can be easily missed becau se the present ing sympto ms mimic those of benign tu mors of the nose . They are often discovered incidenta lly during septoplasty or polypectomy.' Because olfactory neurob lastomas are so uncom mon, few data exis t with respect to optim um management strategies, altho ugh diagnostic and treatment moda lities have improved overthe past 2 decades.l? Treatment recommendations range from a minim ally invasi ve approach" to craniofacial resection combined with radioth erap y. ' In this artic le, we report a new case of olfactory neurob lasto ma . facia l pain, and watering of the eyes . On rhinoscopy, a polypoid mass was see n in the roof of her nose; the mass was not attac hed to the septum or lateral wal l. Her vision in both eyes was normal, and her eye movements were unrestricted. Findings on the rema inder of the head and neck examination were unremarkable. The patient had undergone two surgical procedures elsewhere-3 and 1years prior to presentation-during which intran asal excision of the mass had been attempted. These operations ultimately failed beca use of an incomplete removal of the mass and a lack of postoperative rad iothera py. We performed an intranasa l biop sy with local anesthes ia, which was co mpleted with minima l bleedin g. On histopathologic analysis, the tumor was identified as an olfactory neuroblasto ma (figure I, A) . This finding was confirmed by immunohistochemistry, which was positi ve for chromogranin, synaptop hysin, neuron-spec ific enolase, and neurofi lament ( figure I, B ). Computed tomography (CT) confirmed that the tumor arose from the cr ibriform area; no intracrania l extension was seen (figure 2, A). The ipsilateral anterior and postet hmoid cells were involved, but the maxillary and spheno id sinuses were free oftumor.The mass was removed via a lateral rhi notomy approac h, and the tumor was peeled away complete ly from the cribriform plate with endoscopes.
Case report
Two weeks after surgery, the patient received 6,000 cGy of radiation in 30 fractions . At follow-up 15 months later, she was free of recurrence ( figure 2, B ).
Discussion
Olfactory neuroblastomas arise from olfactoryneuroepithelium, which extends from the roofofthe nose to the area of the superio r turb inates and a portion of the nasal septum.' From there , they ca n readily exte nd into the cribriform plate of the ethmoid sinus. Most of the cases described in the literature involved adults, but 1 case has been reported in a child as young as 2 years of age . 8 Symptom s. The most common symptoms of olfactory neuroblastoma are nasal obstruction, epistaxis, and headache (patients with extensive tumors may have orbit al symptoms suc h as prop tosis and excessive lacrimation)." Beca use most of these symptoms are similar to those of benign nasal disease, olfactory neuroblastoma is ofte n m issed during its early stages and not diagnosed unti l it has reac hed an advanced stage .
In vestigation. High-resolution CT and magnetic resonance imaging can be used as complementary investigations to precisely deli neate the exte nt of the tumor and to defi ne the invo lvement of the cri brifor m plate, ante rior cranial fossa , an d retro max illary space. Endoscopic examination is esse ntia l for eva luating the exte nt of the tumo r and for obtain ing a biopsy specimen.
Microscop ic analysis. The typical histo log ic appearance of an olfactory neuroblastoma inc ludes the presence of character istic cells separated into nests or compartments by fibrovascular septae, neurofibri llary interce llular matrices, and rosette format ions. The histo log ic diagnosis is ofte n co nfounded by the var ious arra ngements of ce lls packed in sheets and by an arc hitecture that is simi lar to many ne urogenic tumors. Immunoh istochem istry, however, can lead to a definitive diagnosis; this tumor is positive for neuroend ocrine markers such as chro mogranin, synapto physi n, neuron-specific enolase, and protein gene produ ct 9.5. 10
Staging. Because ma lignant lesions of the nasa l cavity are so rare an d because many differe nt histo logic types oftumors abou nd, no approved class ification and staging system has been universally accepted.
• The Hyams classification (gra des I thro ugh IV) is based on histo logic differe ntiation; the gra de IV designation is used to describe und ifferentiated sinonasa l carcinomas. I I • More we ll accepted is the Kadis h classific ation syste m (stages A through C), which is based on the clinical spread of the tumor; stage A tumors are confined to the nasal cavity, stage B lesions invo lve the sinuses; and stage C masses invo lve the midd le cranial fossa and the retrob ulbar orbit." Reservat ions about the Kadis h system are based on the premise that there are minima l differences in the biolog ic behav iorofstageA, B, and C tumors.Nev ertheless, tumors in eac h of these classifications behave differently with respect to progression and me tas tasis and , therefore, survival patterns are different.
• Biller et al introd uced yet another class ificat ion system, whic h takes into acco unt the size of the primary tumor and the presence or absence of regional and distant metastasis."
Treatment. Surgical resection is the clear treat ment of choice, but opinions vary as to its extent. Biller et al rec-Volume 84, Number 3 G HAFFAR, SALAHUDDIN ommended craniofacial resection ofall tumors, regardless of whether the y invad e the anterior cranial fossa or are confined to the nasal roof. 13 They advoc ated resection of the dura over the cribriform plate , the olfactory bulb , the entire ethmoid labyrinth, and the anterior and posterior walls of the frontal sinus . Preoperative irradiation appears to have no beneficial effect. Postoperative ly, some authors have recommended radiot herapy only for advanced tumors, wh ile others have suggested that it should be administered to all patients regardless oftumor stage." As of now, craniofacial resection comb ined with radio therapy is cons idere d the go ld sta ndard in the management of these tumors."
Radical surgery of early lesions (Kadish stages A and B) is not performed at all cente rs. The resu lts oftransnasal endoscopic resection followed by radi ation have been reported to be comparable to those ofcraniofacial resection.15 T he pursuit of m inimally invasive techniques has also led to the use of endoscopic resection of the tumor combined with stereotactic irradiation ofthe frontal skull base with a gamma-ray knife.FThis approach ob viates the need for skin incisions and mid face degloving and avoids the morbidity associated with conventional radiation therapy (e.g., optic neuropath y or retinopathy). Neck dissection is indicated only in the presence of nodes ; elective dissection appears to be unnecessary.
The ro le of induction chemotherapy or concurrent chemoradiation therapy has not been defined. We know that olfactory neuroblastoma is chemosensitive and responsive to platinum-based agents.I-" but che motherapy is currently reserved for unresectabl e or recurrent tumors and for metastases.
Metastasis. Olfactory ne urob lastomas have the potential to sprea d regionally. Neck metastas is can occur early in the disease or many years later. Rinaldo et al reviewed 320 cases at 15 centers and foun d that the incidence of both synchronous and metachronous neck metastases varied greatly, ranging from 5 to 100% (mean: 23.4 %) .10As is true for most head and neck cancers , cervical lymphadenopathy augurs poorly and increases the risk of distant metastasis, most oft en to bones."
Recurren ce. Despite agg ressive therapy, recurrence can develop soon after treatment or even several years later. Researchers at the Mayo Clin ic reported that 42% oflocal recurrences de veloped within 5 years postoperatively and that I case recurred as late as 10 yea rs after surgery." In a review of 40 pat ients , Eden et al reported a recurrence rate of 55% ; two-thirds of these patients had locoregional disease, and 39% of them dev eloped recurrences within 5 years of combined-modality (surgery plus radiation) treatment." Fi nally, researchers at the Un iversity ofIowa reported 5-and IO-yea r actuarial disease-free survival rates of 56 an d 42% , respectively:
In conclus ion, olfactory neurob lastoma requires ag-152 gressi ve surgical resection and radiation therapy. Patients must be followed carefully with the understanding that Iocoregional recurrences are common and may arise sev eral years after treatment. The prognosis for long-term survi val is poor.
